Product Overview
The DRI® Barbiturate Assay is intended for the qualitative and semi-quantitative determination of barbiturates in human urine.
The DRI Barbiturates (BAR) reagent is a highly sensitive and reliable immunoassay test that detects the presence of barbiturates in urine samples. Barbiturates are central nervous system depressants, and their abuse can lead to serious health risks. The DRI Barbiturates assay is designed for use in the MEdTest 200 Ensemble platform, a leading drug of abuse testing system.
Product Features
-
The DRI Barbiturates test offers high sensitivity, designed to detect common barbiturates such as phenobarbital, secobarbital, and others at low concentrations.
-
With the MEdTest 200 Ensemble system, results are available quickly, minimizing wait time for end users and allowing for efficient decision-making.
-
Designed to work seamlessly with the MEdTest 200 Ensemble, the reagent ensures ease of use for medical professionals, lab technicians, and other authorized personnel.
-
Ideal for laboratories or settings requiring rapid testing for multiple samples, the DRI Barbiturates reagent integrates perfectly into high-volume workflows.
Product Specifications
| Catalog Number/SKU | MF-5390012247 |
| Application | Toxicology Reagent |
|---|---|
| For Use With | For MedTest 200 Ensemble DOA |
| Form | Ready-to-Use Liquid |
| Sample Type | Urine Sample |
| Specialty | Toxicology |
| Test Category | Drugs of Abuse |
| Test Method | Homogeneous Enzyme Immunoassay (HEIA) |
| Test Name | Barbiturates (BAR) |
| Test Type | Single Drug |
| Volume | 500 mL |
